



High-Risk, Early Breast Cancer: Clinical Features and the Risk of Recurrence for HR+ /HER2- Disease

Incidence of HR+ /HER2- breast cancer

Most patients with early breast cancer (EBC) have hormone receptor-positive (HR+)/HER2-negative (HER2-) disease¹


Breast Cancer Molecular Subtypes at Diagnosis¹



About 70% of EBC is HR+ /HER2-
EBC has no spread detected beyond the breasts and lymph nodes in and around the breasts and has gone only as far as the lymph nodes in the armpit(s).² Some patients with EBC have cancer cells that are **more aggressive and more likely to grow and spread quickly**, which means there is a **higher risk of the cancer recurring**.^{3,4}

Some clinical features of high-risk disease

Patients with HR+ /HER2- breast cancer at high-risk of recurrence may present with⁵





≥4 positive axillary lymph nodes (ALNs)

or 1-3 positive ALNs with



Grade 3 disease



Tumor size ≥5 cm

3.9x

Compared with grade 1 disease, patients with grade 3 tumors have a **3.9x increased risk of distant recurrence** over 10 years⁶


2.0x

Similarly, patients with stage III disease are at a **2.0x increased risk of recurrence** over 10 years compared to patients with stage I disease⁷

As health care providers, it is important to recognize these features associated with a higher risk of recurrence

Recurrence rates

~30% of patients with high-risk, HR+ /HER2- EBC may experience recurrence, often with distant metastases⁵




About 3 in 10 patients with high-risk, HR+ /HER2- EBC will experience disease recurrence within 5 years⁵

Sites of recurrence⁸⁻¹¹

Most disease recurrence occurs at distant sites. Common sites of distant recurrence include the bone, liver, lungs, and brain. Although local and regional recurrences are treated with curative intent, **distant recurrences remain largely incurable but are treatable**


Common sites of distant recurrence: ▶



1. Howlader N, et al. *J Natl Cancer Inst.* 2014;106(5):dju055.
 2. <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/early-stage-breast-cancer>. (Accessed March 3, 2023).
 3. <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/recurrent-cancer>. (Accessed March 3, 2023).
 4. <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/aggressive>. (Accessed March 3, 2023).
 5. Sheffield KM, et al. *Future Oncol.* 2022;18(21):2667-2682.
 6. Holleccek B, et al. *BMC Cancer.* 2019;19(1):520.
 7. Cheng L, et al. *Cancer Epidemiology Biomarkers & Prevention.* 2012;21(5):800-809.
 8. Gerber B, et al. *Dtsch Arztebl Int.* 2010;107(6):85-89.
 9. Cardoso F, et al. *Ann Oncol.* 2020;31(12):1623-1649.
 10. Pan H, et al. *N Engl J Med.* 2017;377(19):1836-1846.
 11. Riggio AI, et al. *Br J Cancer.* 2021;124:13-26.

High-Risk, Early Breast Cancer: Clinical Features and the Risk of Recurrence for HR+ /HER2- Disease

EBC: Clinical and pathological factors associated with a higher risk of recurrence



1. Cheng L, et al. *Cancer Epidemiol Biomarkers Prev.* 2012;21(5):800-809.
 2. Holleccek B, et al. *BMC Cancer.* 2019;19(1):520.
 3. Pan H, et al. *N Engl J Med.* 2017;377(19):1836-1846.